Systemic sclerosis & Raynaud's
An updated overview of Juvenile systemic sclerosis in a French cohort
Authors' conclusion
JSSc is a rare but severe disease requiring rapid, specialized, and multidisciplinary care.
Study context
- Population
- Patients with juvenile SSc onset before age 16, reported by SOFREMIP member practitioners, France
- Participants
- 18 patients8 French centres
- Outcome
- Clinical overview of juvenile systemic sclerosis (jSSc)
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- RP at initial clinical evaluation
- 61%
- Positive for ANA (all children); anti-Scl70 the most common specificity, even in limited cutaneous subsets
- All
- Meeting ACR/EULAR criteria (all except 3 children with overlap syndromes)
- 83%
- Treated with biological agents (RTX and tocilizumab)
- 3
Observational data: associations, not effects.
Further findings
- No deaths or renal crises reported despite frequent GC use at onset
Original publication
An updated overview of Juvenile systemic sclerosis in a French cohort. Pediatr Rheumatol Online J. Published 8 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →